ACADIA PHARMACEUTICALS INCACAD決算レポート
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
ACAD Q4 2025 Key Financial Metrics
売上高
$284.0M
粗利益
$257.8M
営業利益
$17.4M
純利益
$273.6M
粗利益率
90.8%
営業利益率
6.1%
純利益率
96.3%
前年比成長
9.4%
EPS
$1.61
資金フロー
ACADIA PHARMACEUTICALS INC Q4 2025 財務サマリー
ACADIA PHARMACEUTICALS INC reported revenue of $284.0M (up 9.4% YoY) for Q4 2025, with a net profit of $273.6M (up 90.3% YoY) (96.3% margin). Cost of goods sold was $26.2M, operating expenses totaled $240.4M.
主要財務指標
| 総売上高 | $284.0M |
|---|---|
| 純利益 | $273.6M |
| 粗利益率 | 90.8% |
| 営業利益率 | 6.1% |
| 報告期間 | Q4 2025 |
売上内訳
ACADIA PHARMACEUTICALS INC Q4 2025 revenue of $284.0M breaks down across 2 segments, led by Nuplazid at $174.4M (61.4% of total).
| セグメント | 売上高 | 構成比 |
|---|---|---|
| Nuplazid | $174.4M | 61.4% |
| Daybue | $109.6M | 38.6% |
ACADIA PHARMACEUTICALS INC セグメント別売上 — 四半期推移
ACADIA PHARMACEUTICALS INC revenue by segment across the last 4 reported quarters, showing how each business line (such as Nuplazid and Daybue) has evolved quarter over quarter.
| セグメント | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Nuplazid | $174.4M | $177.5M | $168.5M | $159.7M |
| Daybue | $109.6M | $101.1M | $96.1M | $84.6M |
ACADIA PHARMACEUTICALS INC 年度売上推移
ACADIA PHARMACEUTICALS INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $1.1B). Click any linked year to see what changed vs the prior 10-K.
ACADIA PHARMACEUTICALS INC 四半期売上・純利益の履歴
ACADIA PHARMACEUTICALS INC quarterly results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| 四半期 | 売上高 | 売上前年比 | 純利益 | 純利益率 |
|---|---|---|---|---|
| Q4 2025 | $284.0M | +9.4% | $273.6M | 96.3% |
| Q3 2025 | $278.6M | +11.3% | $71.8M | 25.8% |
| Q2 2025 | $264.6M | +9.3% | $26.7M | 10.1% |
| Q1 2025 | $244.3M | +18.7% | $19.0M | 7.8% |
| Q4 2024 | $259.6M | +12.4% | $143.7M | 55.4% |
| Q3 2024 | $250.4M | +18.3% | $32.8M | 13.1% |
| Q2 2024 | $242.0M | +46.4% | $33.4M | 13.8% |
| Q1 2024 | $205.8M | +73.8% | $16.6M | 8.0% |
損益計算書
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 売上高 | $205.8M | $242.0M | $250.4M | $259.6M | $244.3M | $264.6M | $278.6M | $284.0M |
| 前年比成長 | 73.8% | 46.4% | 18.3% | 12.4% | 18.7% | 9.3% | 11.3% | 9.4% |
貸借対照表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 総資産 | $855.1M | $914.1M | $976.9M | $1.19B | $1.13B | $1.23B | $1.33B | $1.56B |
| 総負債 | $391.1M | $397.4M | $399.7M | $455.0M | $367.1M | $403.2M | $413.5M | $336.8M |
| 株主資本 | $464.0M | $516.7M | $577.2M | $732.8M | $765.2M | $822.4M | $917.3M | $1.23B |
キャッシュフロー
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 営業CF | $29.1M | $25.0M | $63.2M | $40.4M | $20.3M | $64.0M | $74.3M | $-48.7M |